市場調査レポート
商品コード
1451624
造影剤市場レポート:タイプ、モダリティ、用途、投与経路、エンドユーザー、地域別、2024-2032Contrast Media Market Report by Type, Modality (X-ray/Computed Tomography, Magnetic Resonance Imaging, Ultrasound), Application, Route of Administration, End User, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
造影剤市場レポート:タイプ、モダリティ、用途、投与経路、エンドユーザー、地域別、2024-2032 |
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2~3営業日
|
世界の造影剤市場規模は2023年に47億米ドルに達しました。今後、IMARC Groupは、市場が2032年までに65億米ドルに達し、2024年から2032年の間に3.7%の成長率(CAGR)を示すと予測しています。
造影剤としても知られる造影剤は、画像モダリティのコントラスト分解能を向上させることで病態の特徴付けを補助する化学薬剤群です。造影剤は、経口、血管内、直腸経路で注射器を通して投与されます。超音波検査、コンピュータ断層撮影(CT)、磁気共鳴画像法(MRI)検査において、対象となる体内の臓器、組織、血管の視認性を高めるのに役立ちます。また、放射線科医が体内の異常組織と正常組織の違いを画像で判断することもできます。その結果、造影剤はヘルスケア業界、特に世界中の放射線科、インターベンショナル・カーディオロジー、画像診断センター、外来手術センター(ASC)などで幅広く使用されています。
様々な慢性疾患に罹患しやすい世界の老年人口の増加は、市場にプラスの影響を与える重要な要因の一つです。がん、神経疾患、心血管疾患の有病率の上昇も、画像診断手技と造影剤に対する需要を大幅に増加させています。これに伴い、低侵襲(MI)医療処置や手術に対する嗜好が高まっています。MI医療処置や手術は、切開創が小さく、術後の痛みが少なく、入院期間が短く、回復が早いため、メーカーにとって有利な成長機会となっています。これとは別に、医療ツーリズムの著しい増加により、放射性医薬品の需要は世界中で増加しています。さらに、造影剤を正確かつ効果的に管理するためのデジタルソリューションの登場が、造影剤の需要を促進しています。これに加え、造影剤製造時の廃棄物発生を最小限に抑える革新的な製品の発売に注力する企業が増加していることも、市場の成長を強めています。さらに、市場をリードする企業数社による大規模な研究開発(R&D)活動への投資の増加は、市場成長を促進すると予測されています。
The global contrast media market size reached US$ 4.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.5 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032.
Contrast media, also known as contrast agents, is a group of chemical agents that aid in the characterization of pathology by improving the contrast resolution of an imaging modality. It is administered through injectors via oral, intravascular, and rectal routes. It helps enhance the visibility of the targeted body organs, tissues, and blood vessels during an ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) scan. It also allows radiologists to determine the difference between aberrant and normal tissues of the body in images. As a result, contrast media finds extensive applications in the healthcare industry, especially in radiology, interventional cardiology, diagnostic imaging centers, and ambulatory surgical centers (ASCs) around the world.
The growing global geriatric population, which is highly susceptible to various chronic medical disorders, represents one of the key factors positively influencing the market. The rising prevalence of cancer, neurological, and cardiovascular diseases are also significantly increasing the demand for diagnostic imaging procedures and contrast media. In line with this, the growing preferences for minimally invasive (MI) medical procedures and surgeries, as they require smaller incisions and cause less postoperative pain, shorter hospital stays, and faster recovery, are offering lucrative growth opportunities to manufacturers. Apart from this, due to a significant rise in medical tourism, the demand for radiopharmaceuticals is increasing across the globe. Furthermore, the advent of digital solutions for precise and effective management of contrast media is driving the demand for contrast media. This, along with the rising focus of several companies on launching innovative products to minimize waste generation during contrast media manufacturing, is strengthening the market growth. Moreover, increasing investments by several leading market players in extensive research and development (R&D) activities are anticipated to propel market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global contrast media market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, modality, application, route of administration and end user.
Iodinated Contrast Media
Gadolinium-based Contrast Media
Microbubble Contrast Media
Barium-based Contrast Media
X-ray/Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Ultrasound
Radiology
Interventional Radiology
Interventional Cardiology
Intravenous/Intrarterial
Oral Route
Rectal Route
Others
Hospital, Clinics and Ambulatory Surgery Centers
Diagnostic Imaging Centers
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bayer AG, Beijing Beilu Pharmaceuticals Company Limited, Bracco S.p.A., General Electric Company, Guerbet, iMAX Diagnostic Imaging Limited, J.B. Chemicals & Pharmaceuticals Limited, Jodas Expoim Pvt. Ltd., Lantheus, Nano Therapeutics Pvt Ltd, SANOCHEMIA Pharmazeutika GmbH, TAEJOON PHARM Co. Ltd. and Trivitron Healthcare.